『On The Pen GLP-1 News』のカバーアート

On The Pen GLP-1 News

On The Pen GLP-1 News

著者: Dave Knapp GLP-1 Industry Insider
無料で聴く

On The Pen is the leading GLP-1 news podcast and platform covering obesity medicine, FDA actions, drug shortages, access policy, and the business of NuSH therapies. The podcast is in the top 1% of all podcasts globally, and On The Pen is a top Substack best-seller.


Dave Knapp GLP-1 Industry Insider
衛生・健康的な生活 身体的病い・疾患
エピソード
  • What Comes After Zepbound? The Biggest ADA 2026 Obesity Drug Breakthroughs
    2026/06/16

    ADA 2026 delivered a massive wave of obesity and diabetes data, and in this episode of On The Pen, Dave Knapp (@manonthemounjaro) sits down with Jen (@JcanNuSH) ​⁠ to break down the molecules, clinical trials, weight loss results, and safety signals that could define the next generation of obesity and diabetes medicine.


    We dive deep into Survodutide, Mazdutide, UBT251, Berobenatide (MET-097), CagriSema, Zenagamtide (formerly Amycretin), Petrelintide, and so much more!


    From GLP-1/glucagon dual agonists to triple agonists targeting GLP-1, GIP, and glucagon, the obesity treatment landscape is becoming more competitive than ever. Which therapies showed the strongest weight loss? Which struggled with tolerability? And what do these results mean for patients living with obesity, type 2 diabetes, MASLD, sleep apnea, and other metabolic diseases?


    In this episode:


    ✅ Survodutide obesity and liver fat reduction data

    ✅ Mazdutide Phase 3 obesity and diabetes results

    ✅ UBT251 triple agonist weight loss data

    ✅ Berobenatide (MET-097) long-acting GLP-1 updates

    ✅ CagriSema diabetes and obesity trial results

    ✅ Zenagamtide (Amycretin) injectable and oral development

    ✅ Petrelintide amylin agonist info

    ✅ Future GLP-1, GIP, glucagon, and amylin therapies


    The future of obesity medicine is no longer just about who produces the most weight loss. It’s about matching the right therapy to the right patient, improving tolerability, and addressing metabolic disease beyond the number on the scale.


    Read more obesity medicine news at obesity.news


    🔗 Linktree: linktr.ee/manonthemounjaro


    #ADA2026 #Retatrutide #CagriSema #Survodutide #Mazdutide #UBT251 #Berobenatide #MET097 #Zenagamtide #Amycretin #Petrelintide #Inisepatide #Elcaglipron #GLP1 #ObesityMedicine #WeightLoss #Type2Diabetes #Zepbound #Mounjaro #Wegovy #GLP1News #ObesityResearch #DiabetesResearch #OnThePen

    続きを読む 一部表示
    1 時間 15 分
  • Retatrutide Just Reached Bariatric Surgery Results
    2026/06/11

    Dave sits down with nurse practitioner and former Retatrutide clinical trial participant David White to break down the biggest obesity headlines from the 2026 American Diabetes Association Conference. Together, they explore the latest data on Retatrutide's potential to deliver bariatric surgery-level weight loss, improve cardiometabolic health, and reshape the future of obesity and type 2 diabetes treatment.


    otplinks.com

    続きを読む 一部表示
    48 分
  • Retatrutide Before FDA Approval? Lilly Just Changed the Conversation
    2026/06/09

    Dave breaks down an unreported Expanded Access Pathway that Eli Lilly has quietly established for Retatrutide.

    続きを読む 一部表示
    21 分
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません